No Data
No Data
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
In the first half of the year, net income of Shengnuo Biotechnology (688117.SH) was 21.7876 million yuan, up 8.14% year on year.
On July 30, Gelunhui announced its 2024 interim report. During the reporting period, it achieved revenue of 0.199 billion yuan, an increase of 14.44% year-on-year; net income attributable to shareholders of the listed company was 21.7876 million yuan, an increase of 8.14% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.122 million yuan, an increase of 106.55% year-on-year; basic earnings per share were 0.19 yuan. During the reporting period, revenue increased by 14.44% compared to the same period last year, mainly due to the injection of somatostatin and atosiban in 2023.
Shengnuo Biotechnology (688117.SH): Plans to extend the "Formulation Industrialization Technology Renovation Project" of the fundraising project to June 2025.
On July 12th, Gelonhui reported that Santen Pharmaceutical (688117.SH) held the 21st meeting of the fourth board of directors and the 20th meeting of the fourth supervisory board on July 12, 2024 and approved the proposal on the delay of some raised investment projects. Considering the progress of the implementation of some raised investment projects (hereinafter referred to as "raised investment projects"), the company agreed to postpone the date when the raised investment project "formulation industrialization technology transformation project" reaches the planned usable status to June 2025.
Shengnuo Biotechnology (688117.SH): The application for the listing approval of Citric Acid Bivalirudin active pharmaceutical ingredient has been obtained.
On July 4th, Gelon Hui announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., recently received the "Approval Letter for Listing Application of Chemical Raw Materials for Citric Acid Bivalirudin Active Pharmaceutical Ingredient" issued by the National Medical Products Administration. Citric acid bivalirudin is used for perioperative antithrombotic therapy for PCI, can specifically bind to GP IIb/IIIa receptors, and inhibit platelet aggregation by blocking the combination of fibrinogen, von Willebrand factor and other adhesion ligands with GP IIb/IIIa. Citric acid bivalirudin not only
ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Popularity With Investors Is Clear
No Data